A Trial of Safety/Efficacy of Test Article in Patients With Interdigital T. Pedis

Interdigital Tinea Pedis Clinical Trial

Official title:
Clinical Trial Protocol DBI-204 Double-Blind, Randomized, Placebo Controlled Trial of the Safety and Efficacy of DBI-001 Gel in Patients With Interdigital Tinea Pedis

Status Terminated

Clinical Trial Summary

Placebo Controlled Trial of the Safety and Efficacy of DBI-001 in Patients with Interdigital Tinea pedis (T. pedis)

Clinical Trial Description

Double-Blind, Randomized, Placebo Controlled Trial of the Safety and Efficacy of DBI-001 Gel in Patients with Interdigital Tinea pedis (T. pedis). The primary objective is to observe the antimicrobial effect of a daily application of DBI-001Gel for 4 weeks in patients with interdigital T. pedis based on the change from culture positive for a dermatophyte to culture negative as determined by routine mycology culture. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04315051
Study type	Interventional
Source	DermBiont, Inc.
Contact
Status	Terminated
Phase	Phase 2
Start date	September 12, 2019
Completion date	June 30, 2020

View Details

See also
	Status	Clinical Trial	Phase
	Completed	`NCT01696799` - Comparative PK Study of Econazole Nitrate Foam and Econazole Nitrate Cream in Subjects With Interdigital Tinea Pedis Aged 12 Years to Less Than 18 Years	Phase 2
	Terminated	`NCT01119742` - Clinical Equivalence of Two Generic Butenafine Hydrochloride 1% Creams as Compared to Lotrimin Ultra Cream in Patients With Interdigital Tinea Pedis	Phase 1